Biolargo, INC

BioLargo CEO Dennis Calvert provided a comprehensive business update during a shareholder town hall, highlighting progress in medical devices, environmental solutions, and advanced battery technology.

BioLargo, Inc. announced its CEO, Dennis P. Calvert, will participate in a shareholder town hall meeting on Discord on May 5, 2026, to provide a company update and answer questions.

BioLargo, Inc. has entered into a purchase agreement with ClearThink Capital Partners, LLC for up to $10 million in common stock over 36 months, enhancing its capital access.

BioLargo, Inc. announced its Annual Report for the year ended December 31, 2025, highlighting disciplined execution and commercialization advancements despite a significant revenue loss.

BioLargo, Inc. announced that two officers converted nearly $100,000 in unpaid salary and expenses into common stock, subject to a lock-up agreement.

BioLargo, Inc. will host an investor webcast on November 14, 2025, to present company updates.

BioLargo reports a substantial 75% revenue decline in Q3 2025 and a $3.8 million credit loss due to a customer default, raising significant going concern doubts.

BioLargo, Inc. reported a significant 38% decline in total revenue and a widened net loss for the six months ended June 30, 2025, raising substantial doubt about its ability to continue as a going concern.

BioLargo's Q1 2025 revenue decreased by 31% compared to Q1 2024, primarily due to lower sales of its private-label pet odor control product, while the company continues to invest in the development and commercialization of its cleantech technologies.

BioLargo, Inc. saw a significant increase in revenue during the third quarter of 2024, primarily driven by sales of its private-label pet odor control product.

BioLargo Inc. saw a significant increase in revenue during the second quarter of 2024, primarily driven by sales of its private-label pet odor control product.

BioLargo's Q1 2024 revenue increased by 27% year-over-year, primarily driven by sales of its private-label pet odor control product, while the company continues to develop its environmental and medical technologies.

BioLargo, Inc. reported a significant increase in net loss and a 56% revenue decrease for fiscal year 2025, primarily driven by a credit loss from a key customer and ongoing litigation.

BioLargo's 2024 10-K filing reveals a 45% revenue increase driven by private-label odor control products, but the company still faces net losses and going concern uncertainties.

BioLargo and Clyra Medical have entered into a new licensing agreement, granting BioLargo exclusive rights to Clyra's iodine technology outside of specific medical fields.

BioLargo, Inc. reports a significant acquisition of common stock by Chief Science Officer Kenneth Reay, subject to a lock-up agreement tied to revenue or market capitalization milestones.

BioLargo, Inc. reports director Dennis P. Calvert acquired shares in exchange for reduced salary and expenses, with certain shares subject to a lock-up agreement.

Director Jack B. Strommen of BioLargo, Inc. acquired stock options valued at $15,000 as compensation for board services.

BIOLARGO, INC. reports that Director Linda Park was granted stock options as compensation for board services.

Christina Bray, a Director at BioLargo, Inc., was granted a stock option for services rendered as a board member.

BioLargo, Inc. director Dennis E. Marshall reports transactions involving stock options and beneficial ownership adjustments.

BioLargo is asking stockholders to approve a reverse stock split to meet the minimum bid price requirement for listing on the Nasdaq Capital Market.

BioLargo is holding its 2024 Annual Meeting of Stockholders on June 13, 2024, to vote on key proposals including the election of directors, executive compensation, auditor ratification, and the adoption of a new equity incentive plan.

BioLargo, Inc. has filed an S-1 registration statement to allow selling stockholders to resell up to 31,730,651 shares of common stock.

BioLargo, Inc. has filed an S-1 registration statement to allow for the resale of up to 30 million shares of its common stock by selling stockholder Clearthink Capital Partners, LLC.

BioLargo, Inc. has filed a registration statement for the potential resale of up to 34,888,449 shares of its common stock by selling stockholders upon exercise of outstanding warrants.